FDA Accepts sNDA for REVTORPYK in PIK3CA-Mutant Breast Cancer, PDUFA Set for June 2027
CELC sits 24% above its 52-week low of $53.54.
Summary
The FDA accepted Celcuity's supplemental application for REVTORPYK in HR+/HER2- advanced breast cancer with a PIK3CA mutation, with a PDUFA goal date of June 25, 2027. This follows the sNDA submission disclosed in the August 26 8-K, which was backed by Phase 3 VIKTORIA-1 data from the PIK3CA mutant cohort. Approval would extend the label to second-line use regardless of PIK3CA status, roughly 40% of HR+/HER2- breast cancers carry that mutation, widening the addressable population beyond the July 14 approval in non-mutant patients. The drug is already commercially available but has generated no product revenue yet, and Q3 launch spending drove the net loss to $73.3 million. The June 2027 review decision is the next binary event for the stock.
At the time of this announcement, CELC was trading at $66.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $53.54 to $151.02. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.